Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Pacific Edge Limited ( (NZ:PEB) ).
Pacific Edge Limited has increased the size of its equity placement to NZ$25.4 million following strong demand, issuing new shares at NZ$0.17 each, a modest discount to its pre‑announcement trading price. The placement was largely taken up by existing institutional and other investors, and will be followed by a retail offer to eligible shareholders targeting up to an additional NZ$6 million at the same price, giving smaller investors an opportunity to participate.
The capital raise is intended to bolster Pacific Edge’s operational capacity, fund ongoing growth initiatives and support efforts to regain Medicare coverage while advancing evidence generation, product development and innovation in bladder cancer diagnostics. Management says the influx of funds will help consolidate the company’s market position and accelerate broader adoption of its Cxbladder tests by U.S. commercial payers and in the Asia‑Pacific region, with the strong investor response underscoring confidence in its clinical data and strategic direction.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company specialising in bladder cancer diagnostic and prognostic tests for patients with hematuria or under surveillance for recurrent disease. Headquartered in Dunedin, New Zealand, it commercialises its Cxbladder suite of non‑invasive genomic urine tests through CLIA‑certified laboratories in New Zealand and the United States, serving markets across the U.S., Australasia, Israel, Asia and South America.
The Cxbladder tests are designed to improve risk stratification of urothelial cancer, enhance patient experience and optimise clinical workflows by better targeting time and resources. Supported by more than two decades of research and over 25 peer‑reviewed publications, Cxbladder has been incorporated into the American Urological Association’s Microhematuria Guideline and has seen broad uptake, including over 130,000 tests ordered by more than 5,000 urologists in the U.S. and wide availability via New Zealand’s public healthcare system.
Average Trading Volume: 527,887
Technical Sentiment Signal: Hold
Current Market Cap: N$177.9M
For an in-depth examination of PEB stock, go to TipRanks’ Overview page.